Search
On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...
The Employee Retirement Income Security Act of 1974 (“ERISA”) has a reputation for being intimidating and understandably so. Although plan sponsors must practically consider business needs and evaluate benefits alongside general labor and employment considerations, ERISA’s fiduciary standards may...
The use of artificial intelligence (AI) to create works of art and inventions raises interesting legal challenges to the protection of intellectual property (IP). The plain language of the Copyright Act and Patent Act present obstacles to inventors and artists who may use or be AI systems. Recent...
Saul Ewing attorneys hosted this fast-paced webinar, providing a list of things you need to know to develop your checklist for legal issues in 2023, from employment, corporate governance, cybersecurity and privacy, intellectual property to tax. Attorneys with specialized knowledge in these areas...
Saul Ewing LLP represented Genesis Unicorn Capital, LLC, in its acquisition of and role as the sole sponsor for Genesis Unicorn Capital Corp. a special purpose acquisition company (SPAC), in the SPAC's $75 Million initial public offering (IPO) of 7,500,000 units at a price of $10.00 per unit. The...
Saul Ewing LLP represented Signal Hill Acquisition Corp., a special purpose acquisition company, in its initial public offering of 10,000,000 units at a price of $10.00 per unit, resulting in gross proceeds of $100,000,000. The units are listed on The Nasdaq Global Market (Nasdaq) and began trading...
Veronica McCarty is a litigator who represents inventors and companies in intellectual property disputes, particularly for inventions involving computing and biopharmaceutical technologies, as well as medical devices. Veronica works on patent trials, including on ANDA bench trials, and she assists...
Industry-Specific, Business-Focused Legal Advice Increased pricing pressure combined with a rise in generic competition and continued regulatory uncertainty have squeezed the margins of life sciences companies. Helping navigate this ever-shifting terrain, Saul Ewing’s Life Sciences Practice consists...
Caroline Patterson brings more than 25 years of legal experience to her work representing practices and professionals in the health care industry in a variety of transactional, corporate, and regulatory matters. Her experience ranges from providing counsel in mergers, acquisitions, sales and private...
Eric Orlinsky co-chairs the firm's Corporate Practice and its Private Equity/Venture Capital subgroup and concentrates his practice in general business and securities law and counsels clients in private equity and venture capital investments, public and private offerings of debt and equity...
Charlie Lizza brings more than 40 years of litigation experience to his representation of pharmaceutical companies in high stakes patent litigation. Mr. Lizza concentrates his practice in Hatch-Waxman ANDA litigation and protecting the intellectual property of branded pharmaceutical and medical...
Joe Lipchitz represents businesses, officers, directors, and high-level executives in the technology, health care, financial services, and media industries in civil litigation nationwide, particularly in high-stakes disputes. Drawing on his more than 20 years of experience as a trial lawyer, Joe...
Saul Ewing attorneys have been helping clients understand and comply with the Affordable Care Act (ACA) since its enactment in 2010. Our ACA Consulting Team consists of experienced employee benefits attorneys who understand how the ACA interacts with laws such as COBRA and HIPAA. Our team tracks the...